Physician profile
Hea Kim
NPI 1386397677
$1,522.88
in general payments reported to CMS, 2019-2025
24 companies · $665 in 2025
The $665 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $43.03 · 2024: $815 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Education: $14.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.92 |
| Education | $14.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $261.19 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.99 | 2024-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $182.12 | 2024-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $175.02 | 2023-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $100.85 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Aimmune Therapeutics, INC. | $72.91 | 2024-2025 | Vowst |
| Celltrion USA INC. | $66.12 | 2023-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $59.47 | 2025 | Omvoh, Jardiance |
| Madrigal Pharmaceuticals | $47.61 | 2024-2025 | Resmetirom, Rezdiffra |
| Ardelyx, INC. | $45.25 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $30.52 | 2024 | Terlivaz |
| Dexcom, INC. | $24.84 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $23.40 | 2025 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $20.93 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.47 | 2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.97 | 2025 | Breztri |
| Gilead Sciences, INC. | $19.42 | 2024 | |
| Avvisto Therapeutics, LLC | $18.91 | 2025 | Cycloset |
| Celgene Corporation | $17.43 | 2024 | Zeposia |
| Evoke Pharma, INC. | $16.00 | 2025 | |
| Pfizer INC. | $15.72 | 2025 | |
| Sandoz INC. | $13.71 | 2024 | |
| Astellas Pharma US INC | $13.61 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $13.42 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hea Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.